Dr Gordon Sanghera is a British biotechnology entrepreneur and chemist, best known as the founder and CEO of Oxford Nanopore Technologies. He led Oxford Nanopore for 21 years leading the company from an Oxford University spinout to listing on the London Stock Exchange in October 2021.
Earlier in his career, he worked at Medisense, where he contributed to the development of blood glucose monitoring technologies which was sold to Abbott Labs for $876M in 1996. He has spent much of his career advancing innovative bioelectronic platforms for glucose monitoring and DNA sequencing methods, and under his leadership, Oxford Nanopore has pioneered portable, real-time sequencing devices that have transformed research in genomics, healthcare, and environmental science.
Gordon was appointed a CBE for his contributions to science and innovation and is widely recognised for helping make rapid and accessible genetic analysis possible worldwide.
Professional position
- Founder and Tech Innovation Advisor, Oxford Nanopore Technologies
